SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Salim A)
 

Sökning: WFRF:(Salim A) > (2005-2009) > Effects of aspirin ...

  • Diener, Hans-ChristophDepartment of Neurology, University Hospital, Essen, Germany (författare)

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial : a double-blind, active and placebo-controlled study.

  • Artikel/kapitelEngelska2008

Förlag, utgivningsår, omfång ...

  • Elsevier,2008
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-81157
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-81157URI
  • https://doi.org/10.1016/S1474-4422(08)70198-4DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:117692079URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • BACKGROUND: The treatment of ischaemic stroke with neuroprotective drugs has been unsuccessful, and whether these compounds can be used to reduce disability after recurrent stroke is unknown. The putative neuroprotective effects of antiplatelet compounds and the angiotensin II receptor antagonist telmisartan were investigated in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial.METHODS: Patients who had had an ischaemic stroke were randomly assigned in a two by two factorial design to receive either 25 mg aspirin (ASA) and 200 mg extended-release dipyridamole (ER-DP) twice a day or 75 mg clopidogrel once a day, and either 80 mg telmisartan or placebo once per day. The predefined endpoints for this substudy were disability after a recurrent stroke, assessed with the modified Rankin scale (mRS) and Barthel index at 3 months, and cognitive function, assessed with the mini-mental state examination (MMSE) score at 4 weeks after randomisation and at the penultimate visit. Analysis was by intention to treat. The study was registered with ClinicalTrials.gov, number NCT00153062.FINDINGS: 20,332 patients (mean age 66 years) were randomised and followed-up for a median of 2.4 years. Recurrent strokes occurred in 916 (9%) patients randomly assigned to ASA with ER-DP and 898 (9%) patients randomly assigned to clopidogrel; 880 (9%) patients randomly assigned to telmisartan and 934 (9%) patients given placebo had recurrent strokes. mRS scores were not statistically different in patients with recurrent stroke who were treated with ASA and ER-DP versus clopidogrel (p=0.38), or with telmisartan versus placebo (p=0.61). There was no significant difference in the proportion of patients with recurrent stroke with a good outcome, as measured with the Barthel index, across all treatment groups. Additionally, there was no significant difference in the median MMSE scores, the percentage of patients with an MMSE score of 24 points or less, the percentage of patients with a drop in MMSE score of 3 points or more between 1 month and the penultimate visit, and the number of patients with dementia among the treatment groups. There were no significant differences in the proportion of patients with cognitive impairment or dementia among the treatment groups.INTERPRETATION: Disability due to recurrent stroke and cognitive decline in patients with ischaemic stroke were not different between the two antiplatelet regimens and were not affected by the preventive use of telmisartan.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Sacco, Ralph L.Department of Neurology, University Hospital, Essen, Germany (författare)
  • Yusuf, SalimDepartment of Neurology, University Hospital, Essen, Germany (författare)
  • Cotton, DanielBoehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA (författare)
  • Ounpuu, StephanieBoehringer Ingelheim, Burlington, Canada (författare)
  • Lawton, William A.Boehringer Ingelheim Ltd, Bracknell, England (författare)
  • Palesch, YukoDepartment of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA (författare)
  • Martin, Reneé H.Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina, Charleston, South Carolina, USA (författare)
  • Albers, Gregory W.Neurology and Neurological Sciences, Stanford University Medical Center, Palo Alto, California, USA (författare)
  • Bath, PhilipStroke Trials Unit, University of Nottingham, Nottingham, England (författare)
  • Bornstein, NatanNeurology Department, Ichilov Medical, Center, Tel-Aviv, Israel (författare)
  • Chan, Bernard P. L.Division of Neurology, Department of Medicine, National University Hospital, Singapore (författare)
  • Chen, Sien-TsongDepartment of Neurology, Chang Gung Memorial Hospital, Taipei, Taiwan (författare)
  • Cunha, LuisNeurology Department, Hospitais da Universidade de Coimbra, Coimbra, Portugal (författare)
  • Dahlöf, BjörnDepartment of Medicine, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden (författare)
  • De Keyser, JacquesDepartment of Neurology, University Medical Center Groningen, Groningen, Netherland (författare)
  • Donnan, Geoffrey A.National Stroke Research Institute, Austin Health, University of Melbourne, Heidelberg West, Australia (författare)
  • Estol, ConradoNeurological Center for Treatment and Research, Buenos Aires, Argentina (författare)
  • Gorelick, PhilipDepartment of Neurology and Rehabilitation, University of Illinois, Chicago, Illinois, USA (författare)
  • Gu, VivianBoehringer Ingelheim Shanghai Pharmaceuticals Co Ltd, Shanghai, China (författare)
  • Hermansson, KarinBoehringer Ingelheim AB, Stockholm, Sweden (författare)
  • Hilbrich, LutzBoehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA (författare)
  • Kaste, MarkkuDepartment of Neurology, Helsinki University Central Hospital, Helsinki, Finland (författare)
  • Lu, ChuanzhenNeurology Department, Huashan Hospital, Shanghai, China (författare)
  • Machnig, ThomasBoehringer Ingelheim GmbH, Ingelheim, Germany (författare)
  • Pais, PremSt John's Medical College, Bangalore, India (författare)
  • Roberts, RobinClinical Trials Methodology Group, McMaster University, Hamilton, Ontario, Canada (författare)
  • Skvortsova, VeronikaNeurology & Neurosurgery Clinic, Russian State Medical University, Moscow, Russia (författare)
  • Teal, PhilipDepartment of Medicine, Neurology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (författare)
  • Toni, DaniloDepartment of Neurological Sciences, University “La Sapienza”, Rome, Italy (författare)
  • VanderMaelen, CamBoehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA (författare)
  • Voigt, ThorBoehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA (författare)
  • Weber, MichaelCardiology Department, SUNY Downstate College of Medicine, New York, USA (författare)
  • Yoon, Byung-WooDepartment of Neurology, Seoul National University Hospital, Seoul, Korea (författare)
  • Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS), study group (författare)
  • von Euler, Mia,1967-(författare)
  • Department of Neurology, University Hospital, Essen, GermanyBoehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Lancet Neurology: Elsevier7:10, s. 875-8841474-44221474-4465

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy